Literature DB >> 12469191

Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.

Kazushi Shigemasa1, Xiurong Tian, Lijun Gu, Yuko Shiroyama, Nobutaka Nagai, Koso Ohama.   

Abstract

To investigate cyclooxygenase-2 (COX-2) expression and its relationship to p53 accumulation in ovarian adenocarcinomas, COX-2 and p53 protein expressions were examined by immunohistochemistry in 86 ovarian adenocarcinomas and six normal ovaries. In addition, COX-2 mRNA expression level was examined by semi-quantitative PCR in 36 ovarian adenocarcinomas. Neither COX-2 expression nor p53 accumulation were detected in normal ovarian surface epithelium or germinal inclusion cyst epithelial cells. In contrast, COX-2 protein expression was detected in 31.4% of adenocarcinomas, and p53 protein accumulation was found in 30.2% of adenocarcinomas. A significantly higher COX-2 expression rate was observed in endometrioid adenocarcinomas than in either mucinous (p=0.019) or clear cell (p=0.021) adenocarcinomas, and a significantly higher p53 accumulation rate was observed in serous adenocarcinomas compared to clear cell adenocarcinomas (p=0.015). p53 accumulation correlated with advanced clinical stage (stage I vs. stage II/III/IV: p=0.007), whereas no correlation was found between COX-2 expression and clinical stage. There was a significant positive correlation between COX-2 expression and p53 accumulation status (p=0.003). Log-rank testing showed that p53 accumulation was significantly correlated with poor patient survival (p=0.004), whereas no correlation was found between COX-2 expression and survival. COX-2 mRNA expression was detected in 72.2% of ovarian adenocarcinomas, and a significant correlation between COX-2 mRNA expression status and immunoreactivity (p=0.023) was observed. These results suggest that COX-2 expression might play an important role in ovarian cancer development and that COX-2 expression in ovarian adenocarcinomas is frequently associated with p53 protein accumulation. COX-2 overexpression in ovarian cancer cells might partly be caused by dysfunctional p53.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469191

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  Effect of photodynamic therapy combined with Celecoxib on expression of cyclooxygenase-2 protein in HeLa cells.

Authors:  Yuanfu Mao; Lishuang Wang; Chen Xu; Shiyu Han
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

2.  Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan Marolt; Andrej Cor
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.

Authors:  Lin Deng; Ding-Qing Feng; Bin Ling
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

4.  Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.

Authors:  Yoshihito Yokoyama; Bing Xin; Tatsuhiko Shigeto; Hideki Mizunuma
Journal:  J Cancer Res Clin Oncol       Date:  2011-06-17       Impact factor: 4.553

5.  Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk.

Authors:  Galina Lurie; Kathryn L Terry; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Rachel T Palmieri; Daniel W Cramer; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2010-06-18       Impact factor: 2.506

6.  Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.

Authors:  Bing Xin; Yoshihito Yokoyama; Tatsuhiko Shigeto; Hideki Mizunuma
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

7.  Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.

Authors:  Nagehan O Barisik; Suheyla Bozkurt; Mahmut Gumus; Isik Kaygusuz; Nimet Karadayi; Emine Bas; Mahmut Bayik; Tulay Tecimer
Journal:  Diagn Pathol       Date:  2010-03-26       Impact factor: 2.644

8.  Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.

Authors:  Wei Li; Hong-he Zhang; Ru-jun Xu; Guang-chao Zhuo; Ye-qing Hu; Juan Li
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

9.  Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.

Authors:  Gabriella Ferrandina; Franco O Ranelletti; Enrica Martinelli; Amelia Paglia; Gian Franco Zannoni; Giovanni Scambia
Journal:  BMC Cancer       Date:  2006-07-11       Impact factor: 4.430

10.  Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours.

Authors:  A Sakamoto; Y Yokoyama; M Umemoto; M Futagami; T Sakamoto; X Bing; H Mizunuma
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.